XNCR News and Press, Xencor Inc.

2026-05-30 13:46:37 ET More on Incyte, Xencor Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript Xe...

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's ...

2026-05-13 03:40:47 ET Xencor, Inc. (XNCR) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:00 PM EDT... Read the full article on Seeking Alpha For further details see: Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26 start -- -- Plamotamab and XmAb657 autoimmune studies on-track for 2H26 pro...

2026-05-05 18:41:19 ET Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 May 5, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclini...

-- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™ format optimizes bispecifics for treatment of autoimmune diseases; first XenLock™ candida...

2026-03-11 13:32:20 ET Xencor, Inc. (XNCR) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT... Read the full article on Seeking Alpha For further details see: Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Trans...

2026-03-05 10:13:32 ET More on Xencor, AstraZeneca PLC AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript AstraZeneca PLC 2025 Q4 - Results - Earnings Call Presentation China drug licen...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that i...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...